Detection of Ophthalmic Acid in Serum from Acetaminophen-Induced Acute Liver Failure Patients Is More Frequent in Non-Survivors

Gurnit Kaur, Elaine M Leslie, Holly Tillman, William M Lee, Diane P Swanlund, Constantine J Karvellas, US Acute Liver Failure Study Group, Anne M Larson, Iris Liou, Oren Fix, Michael Schilsky, Daniel Ganger, Steven H B Han, Robert Fontana, Brendan McGuire, Adrian Reuben, David Koch, Rajender Reddy, R Todd Stravitz, James Hanje, Jody Olson, Ram Subramanian, Constantine J Karvellas, Grace Samuel, Ezmina Lalani, Carla Pezzia, Corron Sanders, Nahid Attar, Linda S Hynan, Valerie Durkalski, Wenle Zhao, Jaime Speiser, Catherine Dillon, Holly Battenhouse, Michelle Gottfried, Gurnit Kaur, Elaine M Leslie, Holly Tillman, William M Lee, Diane P Swanlund, Constantine J Karvellas, US Acute Liver Failure Study Group, Anne M Larson, Iris Liou, Oren Fix, Michael Schilsky, Daniel Ganger, Steven H B Han, Robert Fontana, Brendan McGuire, Adrian Reuben, David Koch, Rajender Reddy, R Todd Stravitz, James Hanje, Jody Olson, Ram Subramanian, Constantine J Karvellas, Grace Samuel, Ezmina Lalani, Carla Pezzia, Corron Sanders, Nahid Attar, Linda S Hynan, Valerie Durkalski, Wenle Zhao, Jaime Speiser, Catherine Dillon, Holly Battenhouse, Michelle Gottfried

Abstract

Background/aim: Acetaminophen (APAP) hepatotoxicity is related to the formation of N-acetyl-p-benzoquinone imine (NAPQI), which is detoxified through conjugation with reduced glutathione (GSH). Ophthalmic acid (OA) is an analogue of GSH in which cysteine is replaced with 2-aminobutyrate. Metabolomics studies of mice with APAP-induced acute liver failure (APAP-ALF) identified OA as a marker of oxidative stress and hepatic GSH consumption. The aim of the current study was to determine whether OA is detectable in APAP-ALF human patients either early (day 2) or late (day 4) and whether OA levels were associated with in-hospital survival in the absence of liver transplant.

Methods: Serum samples from 130 APAP-ALF patients (82 survivors, 48 non-survivors) were analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) and correlated with clinical data from the United States Acute Liver Failure Study Group (US ALFSG) Registry (2004-2011).

Results: Survivors had significantly lower admission bilirubin (4.2 vs. 5.7 mg/dl) and lactate levels (3.3 vs. 6.5 μmol/l, p<0.05 for all). During the first 7 days of the study, survivors were less likely to require mechanical ventilation (55% vs. 88%), vasopressor support (9.8% vs. 67%) or renal replacement therapy (26% vs. 63%, p< 0.001 for all). Non-survivors were more likely to have detectable OA levels early (31% vs. 15%, p = 0.034) and late (27% vs. 11%, p = 0.02). However there were no significant differences in mean OA levels between non-survivors and survivors (early 0.48 vs. 0.36, late 0.43 vs. 0.37, P > 0.5 for all).

Conclusion: OA was detectable more frequently in APAP-ALF non-survivors but mean OA levels were not associated with survival. The routine clinical administration of N-acetyl cysteine could replenish GSH levels and prevent OA production.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1. Ophthalmic acid levels in healthy…
Fig 1. Ophthalmic acid levels in healthy controls compared with surviving and non-surviving APAP-induced ALF patients at Day 2 (early) and Day 4 (late).
Blood samples were collected for 130 patients with APAP-induced ALF on Day 2 and Day 4 after admission into hospital; at Day 21, there were 82 survivors and 48 non-survivors. Serum OA levels were quantified using UPLC-MS-MS. The data are shown as a Box and Whiskers plot with boxes representing the interquartile range, lines representing the entire range, and data points representing the outliers. No statistically significant differences were found between groups using Chi-squared test.

References

    1. O'Grady JG, Williams R. Classification of acute liver failure. Lancet. 1993;342(8873):743 .
    1. O'Grady JG, Schalm SW, Williams R. Acute liver failure: redefining the syndromes. Lancet. 1993;342(8866):273–5. .
    1. Fagan E, Wannan G. Reducing paracetamol overdoses. BMJ. 1996;313(7070):1417–8. .
    1. Larson AM, Polson J, Fontana RJ, Davern TJ, Lalani E, Hynan LS, et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology. 2005;42(6):1364–72. .
    1. Lu SC. Regulation of hepatic glutathione synthesis: current concepts and controversies. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 1999;13(10):1169–83. .
    1. Soga T, Baran R, Suematsu M, Ueno Y, Ikeda S, Sakurakawa T, et al. Differential metabolomics reveals ophthalmic acid as an oxidative stress biomarker indicating hepatic glutathione consumption. The Journal of biological chemistry. 2006;281(24):16768–76. 10.1074/jbc.M601876200 .
    1. Atterbury CE, Maddrey WC, Conn HO. Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy. A controlled, double-blind clinical trial. Am J Dig Dis. 1978;23(5):398–406. Epub 1978/05/01. .
    1. Conn HO, Lieberthal MM, editors. The hepatic coma syndromes and lactulose. Baltimore: Williams & Wilkins; 1979.
    1. Geenen S, Michopoulos F, Kenna JG, Kolaja KL, Westerhoff HV, Wilson I. HPLC-MS/MS methods for the quantitative analysis of ophthalmic acid in rodent plasma and hepatic cell line culture medium. Journal of pharmaceutical and biomedical analysis. 2011;54(5):1128–35. 10.1016/j.jpba.2010.11.038 .
    1. New LS, Chan EC. Evaluation of BEH C18, BEH HILIC, and HSS T3 (C18) column chemistries for the UPLC-MS-MS analysis of glutathione, glutathione disulfide, and ophthalmic acid in mouse liver and human plasma. Journal of chromatographic science. 2008;46(3):209–14. .
    1. Carretero A, Leon Z, Garcia-Canaveras JC, Zaragoza A, Gomez-Lechon MJ, Donato MT, et al. In vitro/in vivo screening of oxidative homeostasis and damage to DNA, protein, and lipids using UPLC/MS-MS. Analytical and bioanalytical chemistry. 2014;406(22):5465–76. 10.1007/s00216-014-7983-5 .
    1. Keays R, Harrison PM, Wendon JA, Forbes A, Gove C, Alexander GJ, et al. Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: a prospective controlled trial. BMJ. 1991;303(6809):1026–9.
    1. Harrison PM, Wendon JA, Gimson AE, Alexander GJ, Williams R. Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure. The New England journal of medicine. 1991;324(26):1852–7. 10.1056/NEJM199106273242604 .
    1. O'Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology. 1989;97(2):439–45. Epub 1989/08/01. .
    1. Bernuau J, Goudeau A, Poynard T, Dubois F, Lesage G, Yvonnet B, et al. Multivariate analysis of prognostic factors in fulminant hepatitis B. Hepatology. 1986;6(4):648–51. .
    1. Donaldson BW, Gopinath R, Wanless IR, Phillips MJ, Cameron R, Roberts EA, et al. The role of transjugular liver biopsy in fulminant liver failure: relation to other prognostic indicators. Hepatology. 1993;18(6):1370–6. .
    1. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335(7624):806–8. 10.1136/

Source: PubMed

3
Abonnieren